Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Ardizzoni A, et al. Among authors: mazzanti p. J Natl Cancer Inst. 2007 Jun 6;99(11):847-57. doi: 10.1093/jnci/djk196. J Natl Cancer Inst. 2007. PMID: 17551145
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.
Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S, Perrone F. Gridelli C, et al. Among authors: mazzanti p. Br J Cancer. 2004 Dec 13;91(12):1996-2004. doi: 10.1038/sj.bjc.6602241. Br J Cancer. 2004. PMID: 15558071 Free PMC article. Clinical Trial.
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
Novello S, Bruzzi P, Barone C, Buosi R, Masotti A, Michetti G, Fioretti M, Barbera S, Spatafora M, Garetto L, Mazzanti P, Dongiovanni V, Selvaggi G, Crinò L, Scagliotti GV. Novello S, et al. Among authors: mazzanti p. Ann Oncol. 2007 May;18(5):903-8. doi: 10.1093/annonc/mdm061. Epub 2007 Mar 9. Ann Oncol. 2007. PMID: 17351253 Free article. Clinical Trial.
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, Buzzi F, De Signoribus G, Tuveri G, Rossi G, Di Lullo L, Sturba F, Morale D, Catanzani S, Pilone A, Bonsignori M, Battelli T. Mazzanti P, et al. Lung Cancer. 2003 Jul;41(1):81-9. doi: 10.1016/s0169-5002(03)00140-5. Lung Cancer. 2003. PMID: 12826316 Clinical Trial.
Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors.
Berardi R, Santinelli A, Brunelli A, Onofri A, Pierantoni C, Scartozzi M, Pisa E, Stramazzotti D, Mazzanti P, Zuccatosta L, Gasparini S, Sabbatini A, Cascinu S. Berardi R, et al. Among authors: mazzanti p. Anal Quant Cytol Histol. 2011 Aug;33(4):196-204. Anal Quant Cytol Histol. 2011. PMID: 21980623
293 results